Web Exclusives

Web Exclusives — March 21, 2025
round Zero were 3 times more likely to have genetic changes associated with an increased risk of blood cancer compared with other first responders.
Read Article

Web Exclusives — February 27, 2025
The researchers noted variations in time to treatment initiation and choice of therapy across the 3 healthcare settings, with factors such as distance from the hospital and income levels playing significant roles in delays of treatment.
Read Article

Web Exclusives — January 17, 2025
Following the conclusion of the OCM, which previously compensated nurses providing navigation services, practices nationwide faced revenue loss and had to adapt nurse assignments accordingly. Despite these financial setbacks, the demand for navigation services remains high due to their pivotal role in patient care and support.
Read Article

Web Exclusives — December 12, 2024
The specificity of ICD-10-CM codes allows providers to communicate correct clinical information to third-party payers and across the healthcare continuum.
Read Article


Web Exclusives — September 25, 2024
Artificial intelligence holds promise for detecting lung cancer if research presented at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer is any indicator.
Read Article

Web Exclusives — September 25, 2024
Patients diagnosed with stage IV lung cancer displayed higher proportions of EGFR mutations compared to those without.
Read Article

Pearls for Boosting Clinical Trial Participation in Underrepresented Populations
Web Exclusives — August 21, 2024
Encouraging diverse populations to participate in clinical trials is key as new FDA guidance released.
Read Article

Web Exclusives — July 1, 2024
Colorectal cancer (CRC) is the second most common cause of cancer-related death in the United States and is the leading cause of death in men aged <50 years.
Read Article

Web Exclusives — June 28, 2024
On June 26, 2024, the FDA approved epcoritamab-bysp (Epkinly; Abbvie and Genmab) as the first and only T-cell engaging bispecific antibody administered subcutaneously for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after ≥2 lines of prior therapy.
Read Article

Page 3 of 14